Research programme: annexin therapeutics - Unigene Laboratories

Drug Profile

Research programme: annexin therapeutics - Unigene Laboratories

Alternative Names: Annexin peptides

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator Unigene Laboratories; University of London
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cardiovascular disorders; Inflammation; Reperfusion injury

Highest Development Phases

  • Suspended Cardiovascular disorders; Inflammation; Reperfusion injury

Most Recent Events

  • 11 Jan 2011 Unigene Laboratories' annexin therapeutics programme is available for licensing. http://www.unigene.com
  • 11 Aug 2007 Preclinical trials in Reperfusion injuries, Cardiovascular disorders, and Inflammation in United Kingdom (unspecified route)
  • 11 Aug 2007 Preclinical trials in Reperfusion injuries, Cardiovascular disorders, and Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top